Department of Radiation Sciences, Oncology, Umeå University, SE-90187 Umeå, Sweden.
Exp Cell Res. 2011 Feb 15;317(4):504-12. doi: 10.1016/j.yexcr.2010.11.005. Epub 2010 Nov 16.
Leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) is a recently discovered negative regulator of growth factor signaling. The LRIG1 integral membrane protein has been demonstrated to regulate various oncogenic receptor tyrosine kinases, including epidermal growth factor (EGF) receptor (EGFR), by cell-autonomous mechanisms. Here, we investigated whether LRIG1 ectodomains were shed, and if LRIG1 could regulate cell proliferation and EGF signaling in a paracrine manner. Cells constitutively shed LRIG1 ectodomains in vitro, and shedding was modulated by known regulators of metalloproteases, including the ADAM17 specific inhibitor TAPI-2. Furthermore, shedding was enhanced by ectopic expression of Adam17. LRIG1 ectodomains appeared to be shed in vivo, as well, as demonstrated by immunoblotting of mouse and human tissue lysates. Ectopic expression of LRIG1 in lymphocytes suppressed EGF signaling in co-cultured fibroblastoid cells, demonstrating that shed LRIG1 ectodomains can function in a paracrine fashion. Purified LRIG1 ectodomains suppressed EGF signaling without any apparent downregulation of EGFR levels. Taken together, the results show that the LRIG1 ectodomain can be proteolytically shed and can function as a non-cell-autonomous regulator of growth factor signaling. Thus, LRIG1 or its ectodomain could have therapeutic potential in the treatment of growth factor receptor-dependent cancers.
富含亮氨酸重复序列和免疫球蛋白样结构域 1(LRIG1)是一种新发现的生长因子信号负调控因子。LRIG1 整合膜蛋白已被证明通过细胞自主机制调节各种致癌受体酪氨酸激酶,包括表皮生长因子(EGF)受体(EGFR)。在这里,我们研究了 LRIG1 细胞外结构域是否被脱落,以及 LRIG1 是否可以通过旁分泌方式调节细胞增殖和 EGF 信号。细胞在体外持续脱落 LRIG1 细胞外结构域,并且脱落可通过已知的金属蛋白酶调节剂来调节,包括 ADAM17 特异性抑制剂 TAPI-2。此外,通过过表达 Adam17,脱落也得到增强。LRIG1 细胞外结构域似乎也在体内脱落,这可通过对小鼠和人组织裂解物进行免疫印迹来证明。LRIG1 在淋巴细胞中的异位表达抑制了共培养成纤维样细胞中的 EGF 信号,表明脱落的 LRIG1 细胞外结构域可以以旁分泌方式发挥作用。纯化的 LRIG1 细胞外结构域抑制 EGF 信号,而 EGFR 水平没有明显下调。总之,这些结果表明 LRIG1 细胞外结构域可以进行蛋白水解脱落,并可以作为生长因子信号的非细胞自主调节剂发挥作用。因此,LRIG1 或其细胞外结构域在治疗依赖生长因子受体的癌症方面可能具有治疗潜力。